Negative association of pretreatment cigarette use with smoking-induced striatal dopamine release in smokers receiving bupropion treatment

Am J Addict. 2016 Sep;25(6):486-92. doi: 10.1111/ajad.12419. Epub 2016 Jul 28.

Abstract

Background and objectives: In an effort to help identify factors that maintain heavy smoking, this study tested the association of pretreatment cigarette use (cigarettes per day) with striatal dopamine release during smoking-cessation treatment.

Methods: Thirteen regular smokers (≥10 cigarettes per day) were evaluated on parameters of smoking behavior, and they entered a smoking cessation treatment protocol, including bupropion administration and individual counseling for 2 months. On week 7 of treatment, 10 of the participants underwent brain scans using [(11) C]raclopride with positron emission tomography to assess smoking-induced dopamine release in the caudate nucleus and putamen, inferred from changes in dopamine D2 -type receptor availability.

Results: Receptor availability, measured as binding potential referred to non-displaceable uptake (BPND ) in both striatal regions re-demonstrated a significant decrease after smoking a cigarette; and pre-treatment cigarette use significantly negatively correlated with smoking-induced dopamine release in the caudate.

Conclusions and significance: The negative association of cigarette use with dopamine release suggests tolerance or down-regulation of the dopamine system by chronic smoking, or a pre-existing condition that promotes more frequent smoking. This association should be regarded as preliminary evidence that warrants verification. (Am J Addict 2016;25:486-492).

MeSH terms

  • Adult
  • Brain / diagnostic imaging
  • Bupropion* / pharmacokinetics
  • Bupropion* / therapeutic use
  • Corpus Striatum* / diagnostic imaging
  • Corpus Striatum* / drug effects
  • Corpus Striatum* / metabolism
  • Dopamine / metabolism*
  • Dopamine Uptake Inhibitors / pharmacokinetics
  • Dopamine Uptake Inhibitors / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Positron Emission Tomography Computed Tomography / methods
  • Positron-Emission Tomography / methods
  • Raclopride* / pharmacokinetics
  • Raclopride* / therapeutic use
  • Receptors, Dopamine D2 / metabolism
  • Smoking / metabolism*
  • Smoking Cessation / methods
  • Statistics as Topic
  • Tobacco Use Disorder* / drug therapy
  • Tobacco Use Disorder* / metabolism
  • Tobacco Use Disorder* / physiopathology

Substances

  • Dopamine Uptake Inhibitors
  • Receptors, Dopamine D2
  • Bupropion
  • Raclopride
  • Dopamine